Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension
Why the study?
Does catheter-based renal denervation reduce systolic blood pressure in patients with drug-resistant hypertension?
Population
Patients with treatment-resistant hypertension on ≥3 antihypertensive drugs and baseline systolic blood…
Comparison
Catheter-based renal denervation using the… vs Medication-only control group.
Design
RCT, randomized
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Supports renal denervation in drug-resistant hypertension; confirms sustained efficacy at 12 months in this RCT.
Structured PICO
Does catheter-based renal denervation reduce systolic blood pressure in patients with drug-resistant hypertension?
P
Population
Patients with treatment-resistant hypertension on ≥3 antihypertensive drugs and baseline systolic blood pressure ≥160 mm Hg (≥150 mm Hg for type 2 diabetics).
I
Intervention
Catheter-based renal denervation using the Symplicity system.
C
Comparator
Medication-only control group (with crossover to renal denervation at 6 months).
O
Outcome
Change in office systolic blood pressure at 12 months (initial group) and 6 months post-procedure (crossover group).surrogate
Renal denervation provides a safe and sustained reduction in blood pressure up to 1 year in patients with drug-resistant hypertension.
Cite This Study
Esler et al. (2012) studied this question.